ArriVent Virtual KOL and Company Event on Firmonertinib Proof-of-Concept Data in EGFR PACC Mutant Non-Small Cell Lung Cancer to be Presented at a Presidential Symposium During the 2024 World Conference on Lung Cancer
DATE: | September 9, 2024 |
---|---|
TIME: | 4:30 PM EDT |
LOCATION: | Virtual |
About The Event
Join ArriVent BioPharma for a virtual KOL event featuring Xiuning Le, MD, PhD (The University of Texas MD Anderson Cancer Center) to discuss the unmet need and current treatment landscape for EGFR non-small cell lung cancer (NSCLC) and ArriVent’s lead development candidate, firmonertinib, an oral, brain penetrant, broadly active EGFR inhibitor.
The event will also feature Stuart Lutzker, MD, PhD, (President R&D, ArriVent BioPharma), who will review the interim randomized Phase 1b FURTHER data for first-line firmonertinib monotherapy in patients with NSCLC harboring EGFR PACC mutations that will be presented as part of a presidential symposium presentation at the 2024 Annual World Conference on Lung Cancer (WCLC) taking place September 7-10, 2024, in San Diego, California.
A live question and answer session will follow the formal presentations.